SOAT1 and classic Hodgkin lymphoma: JAK-STAT related types share similar gene mutation profiles with cHL, and there is already evidence that patients with relapsed and refractory cHL can benefit from treatment of anti-human PD-1 monoclonal antibodies (Younes et al., 2016; Chen et al., 2019).